Geron (GERN) to Release Earnings on Wednesday

Geron (NASDAQ:GERN - Get Free Report) will likely be releasing its Q4 2024 earnings data before the market opens on Wednesday, February 26th. Analysts expect Geron to post earnings of ($0.04) per share and revenue of $45.29 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). The company had revenue of $47.54 million during the quarter, compared to analysts' expectations of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Trading Up 8.1 %

Geron stock traded up $0.13 during trading hours on Thursday, hitting $1.74. The company had a trading volume of 30,098,861 shares, compared to its average volume of 14,710,527. The company has a 50-day moving average price of $3.00 and a two-hundred day moving average price of $3.81. Geron has a 1 year low of $1.46 and a 1 year high of $5.34. The firm has a market cap of $1.05 billion, a P/E ratio of -5.44 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Scotiabank lowered their target price on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating on the stock in a research note on Thursday. HC Wainwright lowered Geron from a "buy" rating to a "neutral" rating in a report on Wednesday. Stifel Nicolaus cut their price objective on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday. Needham & Company LLC lowered their target price on Geron from $7.00 to $5.00 and set a "buy" rating on the stock in a report on Thursday. Finally, B. Riley downgraded shares of Geron from a "buy" rating to a "neutral" rating and cut their price target for the stock from $3.50 to $2.00 in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $5.68.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.